Picture of Laekna logo

2105 Laekna Share Price

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+0.71%
3m-21.71%
6m-70.34%
1yrn/a
Volume Change (%)
10d/3m+106.33%
Price vs... (%)
52w High-76.64%
50d MA+5.59%
200d MA-52.45%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-36.41%
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Laekna EPS forecast chart

Profile Summary

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    July 29th, 2016
    Public Since
    June 29th, 2023
    No. of Employees
    89
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    hk flag iconStock Exchange of Hong Kong Limited
    Shares in Issue
    390,100,350
    Blurred out image of a map
    Address
    SHANGHAI, 200120
    Web
    https://www.laekna.com/
    Phone
    Auditors
    KPMG

    2105 Share Price Performance

    Similar to 2105

    Picture of Abbisko Cayman logo

    Abbisko Cayman

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Akeso logo

    Akeso

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Alphamab Oncology logo

    Alphamab Oncology

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Antengene logo

    Antengene

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Ascentage Pharma International logo

    Ascentage Pharma International

    hk flag iconStock Exchange of Hong Kong Limited

    FAQ